This review summarizes current knowledge in the development of immune checkpoint inhibitors, including antibodies and small molecules.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2023.115465 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel strategy of co-expressing CXCR5 and IL-7 enhances CAR-T cell effectiveness in osteosarcoma.
Front Immunol
October 2024
Shanghai Key Laboratory of Regulatory Biology, School of Life Sciences, East China Normal University, Shanghai, China.
Background: Solid tumors are characterized by a low blood supply, complex stromal architecture, and immunosuppressive milieu, which inhibit CAR-T cell entry and survival. CXCR5 has previously been employed to increase CAR-T cell infiltration into CXCL13+ cancers. On the other hand, IL-7 improves the survival and persistence of T cells inside a solid tumor milieu.
View Article and Find Full Text PDFStrongly quenched activatable theranostic nanogel for precision imaging-guided photodynamic therapy and enhanced immunotherapy.
J Control Release
December 2024
Research Institute, National Cancer Center, 323 Ilsan-ro, Goyang, Gyeonggi-Do 10408, Republic of Korea. Electronic address:
Immune checkpoint inhibitors (ICIs) are innovative immunotherapeutic agents for cancer. However, their low therapeutic efficacy in patients with large or rapidly growing tumors, along with their high cost, represents a notable limitation in their clinical applications. Therefore, new and safe strategies must be developed to enhance the therapeutic efficacy of ICIs in clinical settings.
View Article and Find Full Text PDFThe mechanism of MMP14-positive tumor-associated fibroblast subsets in inhibiting PD-1 immunotherapy for esophageal cancer through exosomal tsRNA-10522.
Funct Integr Genomics
October 2024
Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, NO. 569 Xinsi Road, Xi'an, 710038, Shaanxi, China.
Article Synopsis
- Esophageal cancer (EC) is a serious health issue, and cancer-associated fibroblasts (CAFs) are potential targets for new therapies, particularly regarding how they interact with the tumor microenvironment.
- The study identified and characterized MMP14 CAFs and their role in promoting cancer cell migration and reducing the effectiveness of CD8 T cells, which are crucial for tumor killing, especially in the context of PD-1 immunotherapy.
- Exosomal tsRNA from MMP14 CAFs was found to inhibit CD8 T cell activity, specifically with tsRNA-10522, suggesting that these CAFs could serve as markers for predicting responses to PD-1 immunotherapy in esophageal cancer.
Treatment of tumor-associated macrophages with PD-1 monoclonal antibodies affects vascular generation in cervical cancer via the PD-1/IRE1α/SHP2/HIF1α signaling pathway.
Aging (Albany NY)
August 2024
Department of Radiotherapy, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China.
Objective: To investigate the effect of PD-1 monoclonal antibodies in tumor-associated macrophages on angiogenesis in cervical cancer and its mechanism of action.
Methods: The effect of PD-1 monoclonal antibodies on the progression of cervical cancer was assessed using the nude mouse xenograft model and HE staining; the impact of PD-1 monoclonal antibodies on cervical cancer cell migration was evaluated using wound healing assay and Transwell assay; the effect on vascular formation in cervical cancer cells was examined using an angiogenesis assay; the impact on the expression of related proteins was tested using Western blotting.
Results: PD-1 monoclonal antibodies in tumor-associated macrophages can regulate and thus inhibit the progression of cervical cancer while promoting the expression of SHP2.
Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy.
ACS Appl Mater Interfaces
July 2024
School of Biomedical Engineering & The First Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.
Cancer immunotherapy is developing as the mainstream strategy for treatment of cancer. However, the interaction between the programmed cell death protein-1 (PD-1) and the programmed death ligand 1 (PD-L1) restricts T cell proliferation, resulting in the immune escape of tumor cells. Recently, immune checkpoint inhibitor therapy has achieved clinical success in tumor treatment through blocking the PD-1/PD-L1 checkpoint pathway.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!